* FDA needs more time to weigh product
* No indication delay is linked to UK death
* Vaccine batch recalled following teenager’s death
* Cervarix gets support in Japan
By Susan Heavey
WASHINGTON, Sept 29 (Reuters) – GlaxoSmithKline Plc’s (GSK.L) (GSK.N) bid to sell its Cervarix cervical cancer vaccine in the United States faced further delay on Tuesday and the company recalled a batch of the vaccine in Britain following a teenager’s death.
The U.S. Food and Drug Administration again postponed a decision on the British drugmaker’s application, saying it needed more time to review the product. It was the second deferral by the agency since Glaxo sought approval in 2007.
The delay comes one day after news that a 14-year-old girl in Britain died shortly after receiving the shot, but Glaxo said there was no link between the FDA delay and that case.
“The FDA has not indicated that the extended review in the U.S. is related to that event or to any safety concern,” Glaxo spokeswoman Sarah Alspach told Reuters.